|
1
|
Wood SL, Pernemalm M, Crosbie PA and
Whetton AD: Molecular histology of lung cancer: From targets to
treatments. Cancer Treat Rev. 41:361–375. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carcereny E, Morán T, Capdevila L, Cros S,
Vilà L, de Los Llanos, Gil M, Remón J and Rosell R: The epidermal
growth factor receptor (EGRF) in lung cancer. Transl Respir Med.
3:12015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li LN, Chen WM and Fang QC: Studies on the
extraction and isolation of securinine from securinega suffruticosa
(PALL.) REHD by adsorption with active carbon. Yao Xue Xue Bao.
9:352–358. 1962.(In Chinese). PubMed/NCBI
|
|
4
|
Saito S, Kotera K, Shigematsu N, Ide A,
Sugimoto N, Horii Z, Hanaoka M, Yamawaki Y and Tamura Y: Structure
of securinine. Tetrahedron. 19:2085–2099. 1963. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta K, Chakrabarti A, Rana S, Ramdeo R,
Roth BL, Agarwal ML, Tse W, Agarwal MK and Wald DN: Securinine, a
myeloid differentiation agent with therapeutic potential for AML.
PLoS One. 6:e212032011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Treatment of chronic aplastic anemia with
securinine-analysis of 123 cases. Zhonghua Nei Ke Za Zhi.
22:764–766. 1983.(In Chinese). PubMed/NCBI
|
|
7
|
Neganova ME, Klochkov SG, Afanasieva SV,
Serkova TP, Chudinova ES, Bachurin SO, Reddy VP, Aliev G and
Shevtsova EF: Neuroprotective effects of the securinine-analogues:
Identification of Allomargaritarine as a lead compound. CNS Neurol
Disord Drug Targets. 15:102–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beutler JA, Karbon EW, Brubaker AN, Malik
R, Curtis DR and Enna SJ: Securinine alkaloids: A new class of GABA
receptor antagonist. Brain Res. 330:135–140. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Copperman R, Copperman G and Der
Marderosian A: From Asia securinine-a central nervous stimulant is
used in treatment of amytrophic lateral sclerosis. Pa Med.
76:36–41. 1973.PubMed/NCBI
|
|
10
|
Li M, Han S, Zhang G, Wang Y and Ji Z:
Antiproliferative activity and apoptosis-inducing mechanism of
L-securinine on human breast cancer MCF-7 cells. Pharmazie.
69:217–223. 2014.PubMed/NCBI
|
|
11
|
Han S, Zhang G, Li M, Chen D, Wang Y, Ye W
and Ji Z: L-securinine induces apoptosis in the human promyelocytic
leukemia cell line HL-60 and influences the expression of genes
involved in the PI3K/AKT/mTOR signaling pathway. Oncol Rep.
31:2245–2251. 2014.PubMed/NCBI
|
|
12
|
Choi HJ, Park H, Lee HW and Kwon YG: The
Wnt pathway and the roles for its antagonists, DKKS, in
angiogenesis. IUBMB Life. 64:724–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abdel-Magid AF: Wnt/β-catenin signaling
pathway inhibitors: A promising cancer therapy. ACS Med Chem Lett.
5:956–957. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xue G, Romano E, Massi D and Mandalà M:
Wnt/β-catenin signaling in melanoma: Preclinical rationale and
novel therapeutic insights. Cancer Treat Rev. 49:1–12. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chandra V and Hong KM: Effects of deranged
metabolism on epigenetic changes in cancer. Arch Pharm Res.
38:321–337. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Walter K, Holcomb T, Januario T, Yauch RL,
Du P, Bourgon R, Seshagiri S, Amler LC, Hampton GMS and Shames D:
Discovery and development of DNA methylation-based biomarkers for
lung cancer. Epigenomics. 6:59–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ko M, An J, Pastor WA, Koralov SB,
Rajewsky K and Rao A: TET proteins and 5-methylcytosine oxidation
in hematological cancers. Immunol Rev. 263:6–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carless MA: Investigation of genomic
methylation status using methylation-specific and bisulfite
sequencing polymerase chain reaction. Methods Mol Biol.
1288:193–212. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang M, Zhang Y, Fei J, Chang X, Fan W,
Qian X, Zhang T and Lu D: Rapid quantification of DNA methylation
by measuring relative peak heights in direct bisulfite-PCR
sequencing traces. Lab Invest. 90:282–290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hughes S and Jones JL: The use of multiple
displacement amplified DNA as a control for methylation specific
PCR, pyrosequencing, bisulfite sequencing and methylation-sensitive
restriction enzyme PCR. BMC Mol Biol. 8:912007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reed K, Poulin ML, Yan L and Parissenti
AM: Comparison of bisulfite sequencing PCR with pyrosequencing for
measuring differences in DNA methylation. Anal Biochem. 397:96–106.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chirkin E, Atkatlian W, Do Q, Gaslonde T,
Dufat TH, Michel S, Lemoine P, Genta-Jouve G and Porée FH:
Chiroptical study and absolute configuration of securinine
oxidation products. Nat Prod Res. 29:1235–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Xiao, Ming Zheng and Hong Yan: The
extraction technology of securinine. Agricultural Food Products
Science and Technology. 5:6–1112. 2011.
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Navanesan S, Wahab Abdul N, Manickam S and
Sim KS: Leptospermum flavescens constituent-LF1 causes cell death
through the induction of cell cycle arrest and apoptosis in human
lung carcinoma cells. PLoS One. 10:e01359952015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sood S and Srinivasan R: Alterations in
gene promoter methylation and transcript expression induced by
cisplatin in comparison to 5-Azacytidine in HeLa and SiHa cervical
cancer cell lines. Mol Cell Biochem. 404:181–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nardi-Agmon I and Peled N: Exhaled breath
analysis for the early detection of lung cancer: Recent
developments and future prospects. Lung Cancer (Auckl). 8:31–38.
2017.PubMed/NCBI
|
|
28
|
Chen Z, Mei J, Liu L, Wang G, Li Z, Hou J,
Zhang Q, You Z and Zhang L: PD-L1 expression is associated with
advanced non-small cell lung cancer. Oncol Lett. 12:921–927.
2016.PubMed/NCBI
|
|
29
|
Ge L and Shi R: Progress of EGFR-TKI and
ALK/ROS1 inhibitors in advanced non-small cell lung cancer. Int J
Clin Exp Med. 8:10330–10339. 2015.PubMed/NCBI
|
|
30
|
Atherly AJ and Camidge DR: The
cost-effectiveness of screening lung cancer patients for targeted
drug sensitivity markers. Br J Cancer. 106:1100–1106. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lantermann AB, Chen D, McCutcheon K,
Hoffman G, Frias E, Ruddy D, Rakiec D, Korn J, McAllister G,
Stegmeier F, et al: Inhibition of casein kinase 1 alpha prevents
acquired drug resistance to erlotinib in EGFR-mutant non-small
celllung cancer. Cancer Res. 75:4937–4948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang X, Han SW, Liu H, Zhu L, Chen YX and
Ji ZN: Secreted frizzled-related protein 1 (SFRP1) gene methylation
changes in the human lung adenocarcinoma cells treated with
L-securinine. J Asian Nat Prod Res. 1–19. 2017. View Article : Google Scholar
|
|
33
|
Gills JJ, Granville CA and Dennis PA:
Targeting aberrant signal transduction pathways in lung cancer.
Cancer Biol Ther. 3:147–155. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang XT, Ma YY, Guo K, Xia YJ, Wang HJ,
Li L, He XJ, Huang DS and Tao HQ: Assessing the diagnostic value of
serum Dickkopf-related protein 1 levels in cancer detection: A
case-control study and meta-analysis. Asian Pac J Cancer Prev.
15:9077–9083. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tian J, Xu XJ, Shen L, Yang YP, Zhu R,
Shuai B, Zhu XW, Li CG, Ma C and Lv L: Association of serum Dkk-1
levels with β-catenin in patients with postmenopausal osteoporosis.
J Huazhong Univ Sci Technolog Med Sci. 35:212–218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sonohara F, Inokawa Y, Hayashi M, Kodera Y
and Nomoto S: Epigenetic modulation associated with carcinogenesis
and prognosis of human gastric cancer. Oncol Lett. 13:3363–3368.
2017.PubMed/NCBI
|
|
37
|
Shinjo K and Kondo Y: Targeting cancer
epigenetics: Linking basic biology to clinical medicine. Adv Drug
Deliv Rev. 95:56–64. 2015. View Article : Google Scholar : PubMed/NCBI
|
